EGFR-ASAP1 signalling may contribute to hepatoblastoma (HBL) tumorigenesis and invasiveness, say US-based researchers.
Serum osteoprotegrin levels may eventually be used as a reliable marker for bone loss and osteoporosis risk, at least in women with chronic kidney disease (CKD), a new study reports.
Once-daily daclatasvir therapy for 12 weeks plus sofosbuvir is effective in the treatment of chronic hepatitis C, as shown in a review.
A study suggests that patients with metabolic syndrome (MS) associated with hyperferritinemia (HF), or what is known as dysmetabolic hyperferritinemia (DH), may have normal liver iron concentration (LIC) values.
Combination therapy with daclatasvir and asunaprevir may be safe and effective in patients with chronic genotype 1 hepatitis C virus (HCV) infection and compensated liver cirrhosis, according to a study.
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination attains high SVR 12 rates in HCV-infected patients
Fixed-dose combination of daclatasvir, asunaprevir, and beclabuvir resulted in high rates of sustained virologic response at post-treatment week 12 (SVR12) in Japanese patients infected with HCV genotype 1, as stated in a phase III study.
Entecavir may be more effective than lamivudine in preventing reactivation of hepatits B virus (HBV) in lymphoma patients undergoing chemotherapy, a meta-analysis shows.
Linagliptin is safe and effective for the treatment of type 2 diabetes mellitus (T2DM) patients with liver disease, according to a pooled analysis of 17 randomised, double-blind, placebo-controlled clinical trials.
Resveratrol was found to improve insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease (NAFLD) in a recent study.
Access to primary care or insurance prior to diagnosis is associated with better outcomes in autoimmune hepatitis, according to a recent study.